A recent randomized, placebo-controlled trial has suggested that Pomanox P30, a standardized pomegranate extract from Euromed, may enhance skin hydration and elasticity. The study, known as "Pomaskin," reported reduced pigmentation after just four weeks of supplementation.
Read More
Pomanox P30 is sourced from Mediterranean pomegranates and is standardized to contain at least 30% punicalagins. It is produced using Euromed’s unique water-based Pure-Hydro Process. Andrea Zangara, scientific communication advisor at Euromed, stated that the findings of the Pomaskin study provide a valuable foundation for future formulation development and clinical research in beauty products.
Previous human trials have investigated Pomanox P30's benefits for various health aspects, including cognitive performance, cardiovascular health, and exercise. Earlier in-vitro studies also indicated that the extract might influence collagen and hyaluronic acid metabolism, reduce oxidative stress from UV exposure, and inhibit tyrosinase, an enzyme involved in melanin production.
The latest study involved 64 women aged 30 to 65 with hyperpigmented spots on their faces, who were given either 367 mg or 700 mg of Pomanox P30 or a placebo daily for 12 weeks. While hydration declined in the placebo group, those receiving Pomanox P30 showed maintained skin hydration. Significant improvements in pigmentation were noted from the 367 mg/day group within the first four weeks, with continued positive effects on melanin levels recorded through the study's duration.
At the 12-week mark, the 367 mg/day group demonstrated significantly better skin hydration compared to the placebo. Observations also indicated improved skin elasticity, particularly with the 700 mg/day dosage at both four and 12 weeks, and with the 367 mg/day dosage at 12 weeks. Although improvements in elasticity compared to placebo were noted, they were not statistically significant.
Researchers also explored Pomanox P30’s antioxidant properties and polyphenol metabolism for a deeper understanding of its effects on skin health. At 12 weeks, some non-significant trends were observed, including higher glutathione and superoxide dismutase levels in the 367 mg/day group compared to the placebo. In skin microbiota analyses, there were nominal increases in beneficial bacteria such as Bifidobacterium and Lactobacillus, linked to protective skin mechanisms, alongside a rise in urinary polyphenol metabolites, indicating the absorption and metabolism of pomegranate compounds.
The researchers noted these findings could inform future studies exploring the relationship between pomegranate polyphenols, skin health, and gut microbiota, although effects on skin barrier function and inflammation remain undetermined.